

Maggie C Walter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6037864/publications.pdf>

Version: 2024-02-01

51
papers

1,440
citations

394421

19
h-index

345221

36
g-index

52
all docs

52
docs citations

52
times ranked

2240
citing authors

#	ARTICLE	IF	CITATIONS
1	Health-related Quality of Life and Satisfaction with German Health Care Services in Patients with Charcot-Marie-Tooth Neuropathy. <i>Journal of Neuromuscular Diseases</i> , 2022, 9, 211-220.	2.6	4
2	Cardiac and pulmonary findings in dysferlinopathy: A 3-year, longitudinal study. <i>Muscle and Nerve</i> , 2022, 65, 531-540.	2.2	9
3	Assessing the Relationship of Patient Reported Outcome Measures With Functional Status in Dysferlinopathy: A Rasch Analysis Approach. <i>Frontiers in Neurology</i> , 2022, 13, 828525.	2.4	4
4	Assessment of face validity of a disease model of nonsense mutation Duchenne muscular dystrophy: a multi-national Delphi panel study. <i>Journal of Medical Economics</i> , 2022, 25, 808-816.	2.1	1
5	Slowly Progressive Limb-Girdle Weakness and HyperCKemia – Limb Girdle Muscular Dystrophy or Anti-3-Hydroxy-3-Methylglutaryl-CoA-Reductase-Myopathy?. <i>Journal of Neuromuscular Diseases</i> , 2022, , 1-8.	2.6	2
6	Genome editing for Duchenne muscular dystrophy: a glimpse of the future?. <i>Gene Therapy</i> , 2021, 28, 542-548.	4.5	24
7	Assessing Dysferlinopathy Patients Over Three Years With a New Motor Scale. <i>Annals of Neurology</i> , 2021, 89, 967-978.	5.3	17
8	Miyoshi myopathy and limb girdle muscular dystrophy R2 are the same disease. <i>Neuromuscular Disorders</i> , 2021, 31, 265-280.	0.6	18
9	Improving Care and Empowering Adults Living with SMA: A Call to Action in the New Treatment Era. <i>Journal of Neuromuscular Diseases</i> , 2021, 8, 543-551.	2.6	9
10	Effect of Discontinuation of Nusinersen Treatment in Long-Standing SMA3. <i>Journal of Neuromuscular Diseases</i> , 2021, 8, 537-542.	2.6	3
11	Congenital myopathy and epidermolysis bullosa due to PLEC variant. <i>Neuromuscular Disorders</i> , 2021, 31, 1212-1217.	0.6	4
12	A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 433.	2.7	23
13	SMartCARE Real-World Data on Drug Treatment for Spinal Muscular Atrophy. , 2021, 52, .		0
14	A scalable, clinically severe pig model for Duchenne muscular dystrophy. <i>DMM Disease Models and Mechanisms</i> , 2021, 14, .	2.4	20
15	Tasks and interfaces in primary and specialized palliative care for Duchenne muscular dystrophy – A patients’ perspective. <i>Neuromuscular Disorders</i> , 2020, 30, 975-985.	0.6	8
16	Global FKRP Registry: observations in more than 300 patients with Limb Girdle Muscular Dystrophy R9. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 757-766.	3.7	20
17	Intensive Teenage Activity Is Associated With Greater Muscle Hyperintensity on T1W Magnetic Resonance Imaging in Adults With Dysferlinopathy. <i>Frontiers in Neurology</i> , 2020, 11, 613446.	2.4	3
18	Coagulation disorders in Duchenne muscular dystrophy? Results of a registry-based online survey. <i>Acta Myologica</i> , 2020, 39, 2-12.	1.5	5

#	ARTICLE	IF	CITATIONS
19	De-duplicating patient records from three independent data sources reveals the incidence of rare neuromuscular disorders in Germany. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 152.	2.7	22
20	Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 – A Prospective Observational Study. <i>Journal of Neuromuscular Diseases</i> , 2019, 6, 453-465.	2.6	132
21	MYO-MRI diagnostic protocols in genetic myopathies. <i>Neuromuscular Disorders</i> , 2019, 29, 827-841.	0.6	46
22	SMARtCARE – A platform to collect real-life outcome data of patients with spinal muscular atrophy. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 18.	2.7	67
23	Charcot-Marie-Tooth disease type 2CC due to a frameshift mutation of the neurofilament heavy polypeptide gene in an Austrian family. <i>Neuromuscular Disorders</i> , 2019, 29, 392-397.	0.6	10
24	Cost of illness in Charcot-Marie-Tooth neuropathy. <i>Neurology</i> , 2019, 92, e2027-e2037.	1.1	17
25	Teenage exercise is associated with earlier symptom onset in dysferlinopathy: a retrospective cohort study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 1224-1226.	1.9	19
26	MRI in sarcoglycanopathies: a large international cohort study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 72-77.	1.9	55
27	A new case of limb girdle muscular dystrophy 2G in a Greek patient, founder effect and review of the literature. <i>Neuromuscular Disorders</i> , 2018, 28, 532-537.	0.6	11
28	Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 1071-1081.	1.9	81
29	FV 880. Disorders of Coagulation in Duchenne Muscular Dystrophy? – Results of a Registry-Based Online Questionnaire. <i>Neuropediatrics</i> , 2018, 49, .	0.6	0
30	Recent developments in Duchenne muscular dystrophy: facts and numbers. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2017, 8, 681-685.	7.3	25
31	Biomarkers predict outcome in Charcot-Marie-Tooth disease 1A. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 941-952.	1.9	20
32	Clinical Outcomes in Duchenne Muscular Dystrophy: A Study of 5345 Patients from the TREAT-NMD DMD Global Database. <i>Journal of Neuromuscular Diseases</i> , 2017, 4, 293-306.	2.6	125
33	Rare diagnosis of telethoninopathy (LGMD2G) in a Turkish patient. <i>Neuromuscular Disorders</i> , 2017, 27, 856-860.	0.6	15
34	The multifaceted clinical presentation of VCP-proteinopathy in a Greek family. <i>Acta Myologica</i> , 2017, 36, 203-206.	1.5	8
35	Differential expression and localization of Ankrd2 isoforms in human skeletal and cardiac muscles. <i>Histochemistry and Cell Biology</i> , 2016, 146, 569-584.	1.7	6
36	Prevalence of Pompe disease in 3,076 patients with hyperCKemia and limb-girdle muscular weakness. <i>Neurology</i> , 2016, 87, 295-298.	1.1	60

#	ARTICLE	IF	CITATIONS
37	Progressive muscle proteome changes in a clinically relevant pig model of Duchenne muscular dystrophy. <i>Scientific Reports</i> , 2016, 6, 33362.	3.3	60
38	Disease burden of spinal muscular atrophy in Germany. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 58.	2.7	84
39	The Variant p.(Arg183Trp) in SPTLC2 Causes Late-Onset Hereditary Sensory Neuropathy. <i>NeuroMolecular Medicine</i> , 2016, 18, 81-90.	3.4	18
40	Abnormal proliferation and spontaneous differentiation of myoblasts from a symptomatic female carrier of X-linked Emeryâ€Dreifuss muscular dystrophy. <i>Neuromuscular Disorders</i> , 2015, 25, 127-136.	0.6	21
41	50 years to diagnosis: Autosomal dominant tubular aggregate myopathy caused by a novel STIM1 mutation. <i>Neuromuscular Disorders</i> , 2015, 25, 577-584.	0.6	47
42	Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients. <i>Neuromuscular Disorders</i> , 2014, 24, 1003-1017.	0.6	25
43	Long-term follow-up in patients with CCFDN syndrome. <i>Neurology</i> , 2014, 83, 1337-1344.	1.1	6
44	Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial. <i>Orphanet Journal of Rare Diseases</i> , 2013, 8, 26.	2.7	77
45	Late-onset ptosis and myopathy in a patient with a heterozygous insertion in POLG2. <i>Journal of Neurology</i> , 2010, 257, 1517-1523.	3.6	39
46	Laminopathy presenting as familial atrial fibrillation. <i>International Journal of Cardiology</i> , 2010, 145, 394-396.	1.7	16
47	Deletion of the LMNA initiator codon leading to a neurogenic variant of autosomal dominant Emeryâ€Dreifuss muscular dystrophy. <i>Neuromuscular Disorders</i> , 2005, 15, 40-44.	0.6	38
48	Variable reduction of caveolin-3 in patients with LGMD2B/MM. <i>Journal of Neurology</i> , 2003, 250, 1431-1438.	3.6	43
49	Creatine monohydrate in myotonic dystrophy. <i>Journal of Neurology</i> , 2002, 249, 1717-1722.	3.6	58
50	Novel approaches to treat muscular dystrophies. <i>Expert Opinion on Investigational Drugs</i> , 2001, 10, 695-707.	4.1	4
51	Treatment for inclusion body myositis. <i>The Cochrane Library</i> , 0, , .	2.8	11